Organ-selective approach: Targeting the right biology at the right place for the right time, to optimize the therapeutic index.
At Theravance Biopharma we apply organ-selective expertise to biologically compelling pathways (e.g. JAK-STAT) to discover, develop and commercialize medicines designed to treat localized diseases (e.g. respiratory) non-systemically. By limiting systemic exposure, we have the potential to expand the therapeutic index (TI) of our medicines compared to conventional systemic therapies.
Many systemic therapies often fail to achieve maximal effective concentrations due to dose limiting toxicity. Application of our organ-selective approach can result in medicines that maximize efficacy and patient benefit and at the same time minimize risk.
Our research is focused in the areas of inflammation and immunology, and our pipeline of internally discovered programs is targeted to address significant patient needs. The organ-selective strategy has most recently led to the discovery of the gut-selective pan-JAK inhibitor TD-1473 in inflammatory intestinal diseases and the lung-selective inhaled JAK inhibitor TD-8236 in serious respiratory disease. We plan to advance towards the clinic other research projects with various mechanisms of action, each specifically tailored for the organ of interest (e.g. eye-selective), as we identify and validate potentially appropriate compounds.
In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities across biology, medicinal chemistry, DMPK, technical operations, development, and commercial, in a highly integrated system to efficiently execute our organ-selective approach.
Our expertise in process, analytical and formulation development of organ-selective drugs, coupled with our laboratory and manufacturing capabilities, uniquely enables us to develop and advance drug products of high quality.